Showing 5371-5380 of 5956 results for "".
- Quick Eye Test May Flag Unrecognized Brain Injuryhttps://modernod.com/news/quick-eye-test-may-flag-unrecognized-brain-injury/2477145/A quick, noninvasive, handheld device that detects changes in pupil size may offer rapid assessment of potential brain injury in young athletes who have sustained a high-impact hit to the head but who exhibit no obvious signs of brain injury, according to a
- Nicox Signs Agreement for Zerviate in South Koreahttps://modernod.com/news/nicox-signs-agreement-for-zerviate-in-south-korea/2477143/Nicox announced the signature of an exclusive license agreement with Samil Pharmaceutical for the development and commercialization of Zerviate (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in South Korea. Samil Pharmaceutical i
- New Consensus Recommendations Guide Sjogren’s Syndrome Managementhttps://modernod.com/news/new-consensus-recommendations-guide-sjogrens-syndrome-management/2477140/New consensus-based recommendations from the European League Against Rheumatism (EULAR) address the management of Sjogren’s syndrome with topical and systemic therapies, according to a Reuters report. Sjogren’s syndrome
- Novartis Harnessing AI in Amazon Partnership Aimed at Revamping Drug Manufacturing, Supplyhttps://modernod.com/news/novartis-harnessing-ai-in-amazon-partnership-aimed-at-revamping-drug-manufacturing-supply/2477142/Novartis announced Wednesday that it will work with Amazon’s cloud-computing unit to build a data and analytics platform that seeks to “re-invent” the way medicines are manufactured and delivered. “Four years ago, we started our journey with AWS (Amazon Web Servi
- Aldeyra Therapeutics Announces Topline Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-results-from-part-1-of-adaptive-phase-3-renew-trial-in-dry-eye-disease/2477138/Aldeyra Therapeutics announced positive topline results from Part 1 of the adaptive phase 3 RENEW trial of topical ocular reproxalap in patients with dry eye disease, according to a company news release. “To our knowledge, reproxalap is the first topical dry eye disease drug to demonstrate
- Acuity Eyecare Group Announces Rebranding and New Corporate Namehttps://modernod.com/news/acuity-eyecare-group-announces-rebranding-and-new-corporate-name/2477131/Acuity Eyecare Group, which operates leading eyecare groups across the U.S. and has backing by private equity group Riata Capital, is announcing a new name, AEG Vision, along with other corporate updates, according to a
- Mark McGrath to Headline Celebration at Optometry’s Meeting 2020https://modernod.com/news/mark-mcgrath-to-headline-celebration-at-optometrys-meeting-2020/2477126/The American Optometric Association has announced that it is celebrating the decade of the 90s at its annual Optometry’s Meeting, June 24-28, in National Harbor, Maryland/Washington, D.C. “Mark McGrath’s ’90s Experience” will headline the closing Celebration o
- Air Pollution Linked to Higher Glaucoma Riskhttps://modernod.com/news/air-pollution-linked-to-higher-glaucoma-risk/2477124/People in neighborhoods with higher amounts of fine particulate matter pollution were at least 6% more likely to report having glaucoma than those in the least-polluted areas, according to the findings published in Investigative Ophthalmology & Visual Science. “We have found yet
- GN Corporation: Vision Restored with Corneal Cell Transplant Using a Nano Sheet Techniquehttps://modernod.com/news/gn-corporation-vision-restored-with-corneal-cell-transplant-using-a-nano-sheet-technique/2477121/A novel cell transplantation method to treat corneal endothelial diseases such as bullous keratopathy using a nano-composite gel sheet developed by Japanese scientists was granted Indian patent to GN Corporation (GNC), Japan, according to a company news release. This method was earlier granted a
- Iveric bio Appoints Guangping Gao, PhD, Internationally Recognized Gene Therapy Pioneer as Chief Strategist, Gene Therapyhttps://modernod.com/news/iveric-bio-appoints-guangping-gao-phd-internationally-recognized-gene-therapy-pioneer-as-chief-strategist-gene-therapy/2477122/Iveric bio announced the appointment of Guangping Gao, PhD, as Chief Strategist, Gene Therapy. Dr. Gao brings more than 30 years of scientific research experience in gene-based treatments. As one of the world’s leading gene therapy experts, Dr. Gao’s highly distinguished career includes major con